Brief: Nuvectis Pharma Announces Initiation Of NXP900 Phase 1a Clinical Trial
12/09/2023 13:49
Sept 12 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES INITIATION OF THE NXP900 PHASE
1A
CLINICAL TRIAL
Source text for Eikon: ID:nGNE6pl525
Further company coverage: NVCT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin